1-4 of 4
Authors: Magnus Gisslen
Journal Article
Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption
Journal of Antimicrobial Chemotherapy, Volume 75, Issue 5, May 2020, Pages 1311–1320, https://doi.org/10.1093/jac/dkaa003
Published: 13 February 2020
Journal Article
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 4, April 2016, Pages 1056–1062, https://doi.org/10.1093/jac/dkv427
Published: 24 December 2015
Journal Article
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression Get access
Journal of Antimicrobial Chemotherapy, Volume 70, Issue 5, May 2015, Pages 1513–1516, https://doi.org/10.1093/jac/dku558
Published: 20 January 2015
Journal Article
Antiretroviral drug treatment of CNS HIV-1 infection Get access
Journal of Antimicrobial Chemotherapy, Volume 67, Issue 2, February 2012, Pages 299–311, https://doi.org/10.1093/jac/dkr492
Published: 08 December 2011
